Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001654954-24-015251
Filing Date
2024-12-06
Accepted
2024-12-06 16:54:43
Documents
3
Period of Report
2024-12-02

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT section16.html 3  
1 PRIMARY DOCUMENT section16.xml 3 2132
2 POWER OF ATTORNEY poa-mcgauley.htm EX-24 1575
3 IMAGE poa-mcgauley000.jpg GRAPHIC 104168
  Complete submission text file 0001654954-24-015251.txt   149074
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Issuer) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O GALECTIN THERAPEUTICS INC 7 WELLS AVENUE NEWTON MA 02459
Business Address
MCGAULEY THOMAS (Reporting) CIK: 0001550701 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-34600 | Film No.: 241532985